Literature DB >> 15081949

Research on calpain of Schistosoma japonicum as a vaccine candidate.

Nobuo Ohta1, Takashi Kumagai, Haruhiko Maruyama, Ayako Yoshida, Yongkan He, Renli Zhang.   

Abstract

Vaccine development by the use of calpain of Schistosoma japonicum has been tried in our laboratory. We cloned cDNA encoding the heavy chain of S. japonicum calpain, and prepared recombinant molecule of a possible vaccine region of the heavy chain. When BALB/c mice were immunized with our recombinant calpain of S. japonicum with Freund's complete adjuvant, we observed significant reduction in worm burden (41.2% reduction, P<0.05), and also significant anti-fecundity effects. In this sense, calpain of S. japonicum seems to have infection control as well as anti-disease effects. Mechanisms of vaccine effects of calpain remain to be clarified, however, several effector mechanisms are suspected. In immunized mice, raised level of iNos expression was observed, while adhesion of peritoneal exudates cells were also observed in the presence of calpain-immunized sera, suggesting the possibilities of both cellular and humoral protective mechanisms. We examined tissue distribution of calpain in various developmental stages of S. japonicum. Strong signal was observed around excretory grand of cercariae, and they secreted calpain during their migratory movement tested in vitro. Together with the findings, calpain seems to induce larvicidal effects in the immunized mice. We observed time-course kinetics of antibody production against vaccine candidates in experimental S. japonicum infection in pigs. Although significant levels of antibody production were observed for paramyosin and GST, no significant antibody production was observed for calpain. This suggests that calpain is less immunogenic, and route of immunization and/or choice of adjuvant are important in future trials of calpain vaccine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15081949     DOI: 10.1016/j.parint.2004.01.007

Source DB:  PubMed          Journal:  Parasitol Int        ISSN: 1383-5769            Impact factor:   2.230


  19 in total

1.  Cross-species protection: Schistosoma mansoni Sm-p80 vaccine confers protection against Schistosoma haematobium in hamsters and baboons.

Authors:  Souvik Karmakar; Weidong Zhang; Gul Ahmad; Workineh Torben; Mayeen U Alam; Loc Le; Raymond T Damian; Roman F Wolf; Gary L White; David W Carey; Darrick Carter; Steven G Reed; Afzal A Siddiqui
Journal:  Vaccine       Date:  2014-01-04       Impact factor: 3.641

2.  Sm-p80-based DNA vaccine provides baboons with levels of protection against Schistosoma mansoni infection comparable to those achieved by the irradiated cercarial vaccine.

Authors:  Weidong Zhang; Gul Ahmad; Workineh Torben; Zahid Noor; Loc Le; Raymond T Damian; Roman F Wolf; Gary L White; Maria Chavez-Suarez; Ronald B Podesta; Ronald C Kennedy; Afzal A Siddiqui
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

Review 3.  Schistosomiasis vaccines.

Authors:  Afzal A Siddiqui; Bilal A Siddiqui; Lisa Ganley-Leal
Journal:  Hum Vaccin       Date:  2011-11-01

4.  Schistosoma mansoni antigen Sm-p80: Prophylactic efficacy of a vaccine formulated in human approved plasmid vector and adjuvant (VR 1020 and alum).

Authors:  Weidong Zhang; Gul Ahmad; Workineh Torben; Afzal A Siddiqui
Journal:  Acta Trop       Date:  2011-02-18       Impact factor: 3.112

5.  Use of an Sm-p80-based therapeutic vaccine to kill established adult schistosome parasites in chronically infected baboons.

Authors:  Souvik Karmakar; Weidong Zhang; Gul Ahmad; Workineh Torben; Mayeen U Alam; Loc Le; Raymond T Damian; Roman F Wolf; Gary L White; David W Carey; Darrick Carter; Steven G Reed; Afzal A Siddiqui
Journal:  J Infect Dis       Date:  2014-01-16       Impact factor: 5.226

Review 6.  Current status of vaccines for schistosomiasis.

Authors:  Donald P McManus; Alex Loukas
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

Review 7.  Development of a schistosomiasis vaccine.

Authors:  Adebayo J Molehin; Juan U Rojo; Sabrina Z Siddiqui; Sean A Gray; Darrick Carter; Afzal A Siddiqui
Journal:  Expert Rev Vaccines       Date:  2016-01-13       Impact factor: 5.217

8.  Sm-p80-based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni.

Authors:  G Ahmad; W Torben; W Zhang; M Wyatt; A A Siddiqui
Journal:  Parasite Immunol       Date:  2009-03       Impact factor: 2.280

9.  Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model.

Authors:  Gul Ahmad; Weidong Zhang; Workineh Torben; Raymond T Damian; Roman F Wolf; Gary L White; Maria Chavez-Suarez; Ronald C Kennedy; Afzal A Siddiqui
Journal:  Vaccine       Date:  2009-03-10       Impact factor: 3.641

10.  Prime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine.

Authors:  Gul Ahmad; Weidong Zhang; Workineh Torben; Chad Haskins; Sue Diggs; Zahid Noor; Loc Le; Afzal A Siddiqui
Journal:  Parasitol Res       Date:  2009-10-07       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.